WallStreetZenWallStreetZen

NASDAQ: ANTX
An2 Therapeutics Inc Stock

Open Broker Account
$17.38+2.06 (+13.45%)
Updated Sep 30, 2022
ANTX Price
$17.38
Fair Value Price
$19.49
Market Cap
$337.22M
52 Week Low
$6.88
52 Week High
$23.58
P/E
N/A
P/B
2.91x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.04
Operating Cash Flow
N/A
Beta
1.42
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ANTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ANTX ($17.38) is undervalued by 10.82% relative to our estimate of its Fair Value price of $19.49 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ANTX ($17.38) is not significantly undervalued (10.82%) relative to our estimate of its Fair Value price of $19.49 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ANTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more ANTX due diligence checks available for Premium users.

Be the first to know about important ANTX news, forecast changes, insider trades & much more!

ANTX News

Valuation

ANTX fair value

Fair Value of ANTX stock based on Discounted Cash Flow (DCF)
Price
$17.38
Fair Value
$19.49
Undervalued by
10.82%
ANTX ($17.38) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ANTX ($17.38) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation

ANTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.91x
Industry
4.39x
ANTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ANTX's financial health

Profit margin

Revenue
$0.0
Net Income
-$10.1M
Profit Margin
0%

Assets to liabilities

Assets
$120.0M
Liabilities
$4.2M
Debt to equity
0.04
ANTX's short-term assets ($116.88M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ANTX's short-term assets ($116.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ANTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$9.6M
Investing
-$39.5M
Financing
$7.2M

ANTX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ANTX$337.22M+13.45%N/A2.91x
HUMA$335.80M-2.98%1.31x2.36x
ALLK$335.65M+9.29%-0.83x1.51x
IVVD$340.64M+3.30%-4.89x0.82x
DBVT$332.85M-2.21%-2.64x1.36x

An2 Therapeutics Stock FAQ

What is An2 Therapeutics's quote symbol?

NASDAQ: ANTX) An2 Therapeutics trades on the NASDAQ under the ticker symbol ANTX. An2 Therapeutics stock quotes can also be displayed as NASDAQ: ANTX.

If you're new to stock investing, here's how to buy An2 Therapeutics stock.

What is the 52 week high and low for An2 Therapeutics (NASDAQ: ANTX)?

(NASDAQ: ANTX) An2 Therapeutics's 52-week high was $23.58, and its 52-week low was $6.88. It is currently -26.29% from its 52-week high and 152.65% from its 52-week low.

How much is An2 Therapeutics's stock price per share?

(NASDAQ: ANTX) An2 Therapeutics stock price per share is $17.38 today (as of Sep 30, 2022).

What is An2 Therapeutics's Market Cap?

(NASDAQ: ANTX) An2 Therapeutics's market cap is $337.22M, as of Oct 2, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

An2 Therapeutics's market cap is calculated by multiplying ANTX's current stock price of $17.38 by ANTX's total outstanding shares of 19,402,658.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.